Sanofi, GSK variant-specific COVID shot found effective against Omicron

Posted on AllSides June 24th, 2022
From The Center
REUTERS/Benoit Tessier

PARIS/LONDON, June 24 (Reuters) - Late-stage data on an experimental COVID-19 vaccine from Sanofi (SASY.PA) and GSK (GSK.L) has showed the shot confers protection against the Omicron variant of the virus, the companies said on Friday.

The so-called bivalent vaccine targets the Beta variant - first identified in South Africa - as well as the original Wuhan strain of the virus.

In a trial involving 13,000 adults, the vaccine demonstrated an efficacy rate of 64.7% against symptomatic COVID, and 72% efficacy against infections specifically caused by the Omicron variant.

When used in people who...

Read full story

Reuters

AllSides Media Bias Rating: Center
AllSides Media Bias Rating: Center
106704/84317
See full bias rating for Reuters
Learn about media bias
https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-says-covid-19-vaccine-candidate-yields-positive-trial-data-2022-06-24/REUTERS/Benoit Tessier

More News about Coronavirus from the Left, Center and Right

From the Left

From the Center

From the Right